SLC46A2

Across TCGA pan-cancer cohorts, SLC46A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC46A2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC46A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC46A2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

THYM, LUSC, and LIHC are the cancer types where SLC46A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	OS	Median	II,III,IV	0.198	0.745	<.001	24	view →
LIHC	OS	Median	II,III,IV	0.158	0.617	.010	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	0.156	0.493	.020	3	view →
STAD	DFS	Median	II,III,IV	1.000	0.631	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC46A2–THYM (OS)

Open the THYM breakdown →